Mechanisms of multidrug resistance in bladder cancer: the role of the nuclear membrane


Featherstone, Jonathan Mark (2007) Mechanisms of multidrug resistance in bladder cancer: the role of the nuclear membrane. University of Southampton, School of Medicine, Doctoral Thesis , 326pp.

Download

[img] PDF
Download (36Mb)

Description/Abstract

Multidrug resistance (MDR) describes the phenomenon whereby cancer cells
exposed to a single cytotoxic drug develop cross resistance to numerous other
structurally unrelated chemotherapeutics. The development of MDR is a major
cause of cancer chemotherapy treatment failure in all types of cancer.

Numerous mechanisms of MDR have been elucidated which include ATPbinding
cassette (ABC) transporter proteins, cytoplasmic vaults, alterations in
topoisomerase II and increased expression of glutathione-S-transferases, all of
which result in reduced chemotherapeutic efficacy.

Superficial bladder cancer is commonly treated with adjuvant intravesical
chemotherapy using mitomycin C or epirubicin (an anthracycline), following
surgical resection. However, despite this treatment, the recurrence rates of
these tumours can approach 60%. This high recurrence rate represents the
development of MDR in many cases.

Previous work using anthracycline fluorescence has shown that MDR cells
have reduced levels of anthracycline uptake and also demonstrate a
characteristic nuclear sparing of drug uptake. This nuclear sparing
phenomenon in MDR cells transcends tissue type and suggests that the
nuclear membrane may also play a role in MDR.

The work described herein discusses the current role of chemotherapy in the
treatment of superficial bladder cancer, mechanisms of MDR and the role of the
nuclear membrane in MDR. Following this our investigation of the role of the
nuclear membrane is described, using a number of novel techniques including
cell fusion and microinjection. In addition, we investigated MDR modulation by
verapamil, with analysis of changes in cellular, cytoplasmic and nuclear drug
uptake mediated by this known MDR reversing agent.

Item Type: Thesis (Doctoral)
Subjects: R Medicine > RM Therapeutics. Pharmacology
R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Q Science > QP Physiology
Divisions: University Structure - Pre August 2011 > School of Medicine > Cancer Sciences
ePrint ID: 67628
Date Deposited: 28 Aug 2009
Last Modified: 27 Mar 2014 18:48
URI: http://eprints.soton.ac.uk/id/eprint/67628

Actions (login required)

View Item View Item

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics